18
Participants
Start Date
October 8, 2015
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Sorafenib
Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
Cyclophosphamide
250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
Topotecan
0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
University of North Carolina, Chapel Hill
Children's Healthcare of Atlanta, Atlanta
C.S Mott Children's Hospital, Ann Arbor
University of Chicago, Comer Children's Hospital, Chicago
Cook Children's Healthcare System, Fort Worth
Children Hospital of Colorado, Aurora
UCSF Comprehensive Cancer Center, San Francisco
Children's Hospital and Regional Medical Center - Seattle, Seattle
Children's Hospital Los Angeles, Los Angeles
Childrens Hospital Boston, Dana-Farber Cancer Institute., Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Hospital for Sick Children, Toronto
Collaborators (1)
University of California, San Francisco
OTHER
Children's Hospital Los Angeles
OTHER
Lucile Packard Children's Hospital
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
University of Michigan
OTHER
Seattle Children's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER
The Hospital for Sick Children
OTHER
Children's Healthcare of Atlanta
OTHER
University of Chicago
OTHER
Cook Children's Health Care System
OTHER
Children's Hospital Colorado
OTHER
New Approaches to Neuroblastoma Therapy Consortium
OTHER